Supervisory Board

Nicholas Haggar is the Chief Executive of HealthQube Ltd – a UK-based investment, analytics and consultancy platform. With over thirty years of experience in leading and building pharmaceutical businesses, Nicholas brings deep sector knowledge to the Formycon Supervisory Board. Nicholas has successfully delivered strong growth, innovation and increased access to medicines working in blue chip listed pharmaceutical companies, family-owned companies and private equity backed enterprises. With an MBA from Cranfield School of Management and a Bachelors Degree in Industrial and Manufacturing Systems Engineering, Nicholas began his professional career in pharmaceutical technical operations before moving into commercial and enterprise leadership. Nicholas serves on the Zentiva board since 2023, having been CEO of Zentiva following its carve-out from Sanofi in 2018. Nicholas has been active in the biosimilar space for the last 15 years.

Klaus Röhrig is founding partner of Active Ownership Group (AOC). He serves as Member of the Board of Agfa-Gevaert NV and of Francotyp-Postalia Holding AG.

Before founding AOC, he was at Elliott Associates, responsible for the funds’ investments in the German speaking countries. Klaus Röhrig started his career at Credit Suisse First Boston in London, focusing on corporate finance and M&A for technology companies. Throughout his career he focused on identifying investment opportunities, structuring of investments and process-driven value creation.

Klaus Röhrig holds a Master of Economics and Business Administration from Vienna University of Economics and Business Administration.

Dr. Bodo Coldewey, born 1971, completed his studies in business engineering at the Technical University of Kaiserslautern and his doctorate at the Leipzig Graduate School of Management.

Since 1997, he has worked in consulting (KPMG), private equity (3i) and corporate banking (OLB). He has been Managing Director of the family office WEGA Invest GmbH since 2013. WEGA supports its shareholders in the management of a globally diversified investment portfolio as well as in the management of direct investments.

The focus of Dr. Coldewey’s professional activities has always been on supporting shareholders and management in corporate improvements, financing and transactions.

Colin Bond was CFO of Sandoz until June 2024. Previously he was CFO of Vifor Pharma from 2016 to 2022, and CFO of Evotec AG from 2010 to 2016. During his early career, he worked as auditor and management consultant for PricewaterhouseCoopers, Arthur Andersen and Procter & Gamble. He is a Fellow of the Institute of Chartered Accountants in England and Wales, and a member of the Royal Pharmaceutical Society of Great Britain. Colin Bond holds a Bachelor of Science degree in pharmacy and a master’s degree in business administration from London Business School. He is a member of the board of directors of BioPharma Credit PLC and served as a board member of Siegfried Holding AG from 2013 until April 2023. Colin Bond is a citizen of Great Britain and Switzerland.